Advertisement
Vaccines
Subscribe to Vaccines

The Lead

Heat blamed for spray vaccine's failure against swine flu

February 26, 2015 1:10 pm | by Mike Stobbe, AP Medical Writer, Associated Press | News | Comments

The makers of the nasal spray version of the flu vaccine say they now know why it didn't protect young children against swine flu—the doses got too warm. The spray FluMist works well for most flu strains, but small studies found it didn't work very well against the swine flu bug that first emerged in 2009.

Washington state panel mulls bill to trim vaccine exemptions

February 17, 2015 4:28 pm | by Rachel La Corte,Associated Press | News | Comments

Personal or philosophical opposition to vaccines would not be an authorized exemption for the...

Vaccine opposition has ebbed and flowed over centuries

February 14, 2015 3:49 am | by Mike Stobbe, AP Medical Writer, Associated Press | News | Comments

They're considered one of mankind's greatest medical achievements, yet people have balked at...

Nasty flu season has peaked, is retreating

February 13, 2015 2:16 pm | by Mike Stobbe, AP Medical Writer, Associated Press | News | Comments

A new report shows this winter's nasty flu season has peaked and is clearly retreating. The flu...

View Sample

FREE Email Newsletter

Twists, turns, eventually lead to promising Ebola vaccine

February 9, 2015 4:18 am | by Lauran Neergaard, AP Medical Writer, Associated Press | News | Comments

It took 16 years of twists and turns. Over and over, Dr. Nancy Sullivan thought she was close to an Ebola vaccine, only to see the next experiment fail. "A case of resuscitation more than once," is how the National Institutes of Health researcher describes the journey.

Debate over vaccine requirements forges strange alliance

February 6, 2015 1:13 pm | by Nicholas Riccardi, Associated Press | News | Comments

The debate over whether parents should be required to get their children vaccinated against measles has created strange alliances, putting some liberal parents on the same side as Republican conservatives. While the two parties are not cleanly divided on the issue in the nation's state legislatures, it is increasingly the GOP that resists efforts to stiffen requirements on vaccinating kids.

Evaluating strategies for HIV vaccination

February 6, 2015 11:21 am | by Anne Trafton, MIT News Office | News | Comments

Through an investigation of a fundamental process that guides the maturation of immune cells, researchers have revealed new insights into possible ways to vaccinate people to generate potent antibodies of the type that are predicted to offer protection against diverse strains of the highly mutable HIV. 

Advertisement

Federal health officials face tough questions on flu vaccine

February 3, 2015 1:20 pm | by Lauran Neergaard, AP Medical Writer, Associated Press | News | Comments

Federal health officials are facing questioning about why this year's flu vaccine isn't giving good protection against the winter menace. This is a particularly bad flu season, and one reason is that the most common flu strain isn't a good match to this year's vaccine. Lawmakers on Tuesday asked why the Centers for Disease Control and Prevention didn't act months ago when concerns first arose to create a better-matched vaccine.

Toward a cocaine vaccine to help addicts kick the habit

January 22, 2015 8:44 am | by American Chemical Society | News | Comments

In their decades-long search for vaccines against drugs of abuse, scientists have hit upon a new approach to annul cocaine’s addictive buzz. They report in Molecular Pharmaceutics that their strategy, which they tested on mice, harnesses a bacterial protein to trigger an immune system attack on the drug if it enters the body. This response could dull cocaine’s psychotropic effects and potentially help users of the drug kick the habit.

Flu vaccine 23% effective

January 16, 2015 2:04 pm | by Mike Stobbe, AP Medical Writer, Associated Press | News | Comments

As predicted, this year's flu vaccine is doing a pretty crummy job. It's only 23% effective, primarily because it doesn't include the bug that is making most people sick, according to a government study released today. That's one of the worst performances in the last decade, since U.S. health officials started routinely tracking how well vaccines work. In the best flu seasons, the vaccines were 50 to 60% effective.

New approach may lead to inhalable vaccines for influenza, pneumonia

January 8, 2015 9:29 am | by Matt Shipman, News Services, North Carolina State Univ. | News | Comments

Researchers at North Carolina State Univ. and the Univ. of North Carolina at Chapel Hill have uncovered a novel approach to creating inhalable vaccines using nanoparticles that shows promise for targeting lung-specific diseases, such as influenza, pneumonia and tuberculosis.

CDC: Flu season continues to worsen, could peak this month

January 5, 2015 5:35 pm | by By Mike Stobbe, AP Medical Writer, Associated Press | News | Comments

The flu is now widespread in all but seven states, and hospitalization rates match the dismal season two years ago. While health officials fear this will be an unusually bad year, it's too soon to say. The latest figures released Monday by the CDC show the flu hitting hard in most of the 43 states where the illness was widespread. But the flu was not yet rampant in populous states like California and New York.

Advertisement

HIV vaccines should avoid viral target cells

January 5, 2015 8:09 am | by Lisa Newbern, Emory Univ. | News | Comments

Vaccines designed to protect against HIV can backfire and lead to increased rates of infection. This unfortunate effect has been seen in more than one vaccine clinical trial. Scientists at Emory Univ. have newly published results that support a straightforward explanation for the backfire effect: vaccination may increase the number of immune cells that serve as viral targets.

Grant Supports Use of Data Science to Optimize HIV Care

December 30, 2014 9:30 am | by Brown University | News | Comments

HIV can be treated, but not every infection responds the same way. Treatment requires monitoring and testing, a practice that can become expensive for health care systems in the developing world.                                    

Improving Patient Access through Public-Private Partnerships

December 15, 2014 1:20 pm | by Brian Goff, Global Franchise Head, Hemophilia, Baxter BioScience | Articles | Comments

As the health care industry is undergoing a rapid transformation driven by evolving economic and regulatory demands, the biopharmaceutical industry also faces numerous challenges in meeting the needs of patients around the globe. Emerging markets are faced with the challenges of ensuring access to innovative, personalized treatments for patients with critical or rare conditions.

Ebola vaccine trial suspended after side effects

December 11, 2014 12:12 pm | by Associated Press | News | Comments

Swiss researchers have suspended the testing of one of the leading Ebola vaccine candidates after some volunteers reported unexpected side effects.                             

Injectable 3-D vaccines could fight cancer, infectious diseases

December 8, 2014 4:13 pm | by Kat J. McAlpine, Wyss Institute for Biologically Inspired Engineering | News | Comments

One of the reasons cancer is so deadly is that it can evade attack from the body's immune system, which allows tumors to flourish and spread. Scientists can try to induce the immune system, known as immunotherapy, to go into attack mode to fight cancer and to build long lasting immune resistance to cancer cells. Now, researchers have developed a non–surgical injection of programmable biomaterial to do so.

Advertisement

Flu vaccine doesn’t protect against most dominant strain

December 5, 2014 9:08 am | by Associated Press, Mike Stobbe | News | Comments

The flu vaccine may not be very effective this winter, according to U.S. health officials who worry this may lead to more serious illnesses and deaths. Flu season has begun to ramp up, and officials say the vaccine does not protect well against the dominant strain seen most commonly so far this year. That strain tends to cause more deaths and hospitalizations, especially in the elderly.

Ebola vaccine seems safe in first-stage testing

November 26, 2014 6:00 pm | by By Lauran Neergaard - AP Medical Writer - Associated Press | News | Comments

An experimental Ebola vaccine appears safe and triggered signs of immune protection in the first 20 volunteers to test it, U.S. researchers reported. The vaccine is designed to spur the immune system's production of anti-Ebola antibodies, and people developed them within four weeks of getting the shots at the National Institutes of Health.

A hybrid vehicle that delivers DNA

November 26, 2014 7:46 am | by Cory Nealon, Univ. at Buffalo | News | Comments

A new hybrid vehicle is under development. Its performance isn’t measured by the distance it travels, but rather the delivery of its cargo: vaccines that contain genetically engineered DNA to fight HIV, cancer, influenza and other maladies. The technology is a biomedical advancement that could help unleash the potential of DNA vaccines, which despite much research, have yet to make a significant impact in the treatment of major illnesses.

Government wants more clinical trial results made public

November 19, 2014 3:00 pm | by Lauran Neergaard - AP Medical Writer - Associated Press | News | Comments

The government proposed new rules Wednesday to make it easier for doctors and patients to learn if clinical trials of treatments worked or not. Thousands of Americans participate in clinical trials every year, testing new treatments, comparing old ones or helping to uncover general knowledge about health. Many of the studies are reported in scientific journals and trumpeted in the news.

Biochemists build largest synthetic molecular “cage” ever

November 19, 2014 10:26 am | by Stuart Wolpert, Univ. of California, Los Angeles | News | Comments

Univ. of California, Los Angeles biochemists have created the largest-ever protein that self-assembles into a molecular “cage.” The research could lead to synthetic vaccines that protect people from the flu, HIV and other diseases. At a size hundreds of times smaller than a human cell, it also could lead to new methods of delivering pharmaceuticals inside of cells, or to the creation of new nanoscale materials.

Study will test survivors' blood to treat Ebola

November 18, 2014 11:00 pm | by Marilynn Marchione - AP Chief Medical Writer - Associated Press | News | Comments

A coalition of companies and aid groups announced plans Tuesday to test experimental drugs and collect blood plasma from Ebola survivors to treat new victims of the disease in West Africa. Plasma from survivors contains antibodies, substances the immune system makes to fight the virus.

Scientists reveal weak spots in Ebola’s defenses

November 18, 2014 9:27 am | by The Scripps Research Institute | News | Comments

Scientists at The Scripps Research Institute have identified weak spots on the surface of Ebola virus that are targeted by the antibodies in ZMapp, the experimental drug cocktail administered to several patients during the recent Ebola outbreak. The study provides a revealing 3-D picture of how the ZMapp antibodies bind to Ebola virus.

Ebola workers ask Congress for help

November 12, 2014 3:58 am | by Lauran Neergaard - Associated Press - Associated Press | News | Comments

Health workers on the front line of the Ebola crisis say the need for urgent help isn't letting up, as Congress begins considering President Barack Obama's $6.2 billion emergency aid request to fight the disease. Despite reports that the number of infections is slowing in some parts of West Africa, cases still are rising in other areas.

Inhaled Ebola vaccine may offer long-term protection from virus

November 3, 2014 1:43 pm | by J.B. Bird, Univ. of Texas at Austin | News | Comments

A potentially breathable, respiratory vaccine in development has been shown to provide long-term protection for non-human primates against the deadly Ebola virus. Results from a recent pre-clinical study represent the only proof to date that a single dose of a non-injectable vaccine platform for Ebola is long lasting, which could have significant global implications in controlling future outbreaks.

EU seeking to create $1.27 billion Ebola fund

October 20, 2014 10:27 am | by Raf Casert - Associated Press - Associated Press | News | Comments

European Union nations are working to reach 1 billion euros ($1.27 billion) in aid by the end of the week to fight Ebola in West Africa and are seeking a common approach to the crisis.EU foreign ministers began a week of talks Monday so their 28 leaders can agree by Friday on better measures to fight Ebola, anything from financial aid to common repatriation procedures, more Ebola treatment facilities and better training for health workers.

ORNL joins global fight against polio

October 17, 2014 8:36 am | by Christopher R. Samoray, Oak Ridge National Laboratory | News | Comments

The new Urban Dynamics Institute at Oak Ridge National Laboratory is working with the Bill & Melinda Gates Foundation to aid polio vaccination efforts in developing countries. Teams at the institute will apply big data analysis to population dynamics in Nigeria, allowing polio vaccination crews to better estimate the amount of vaccine needed and to target areas of priority, saving time and money in eradicating the disease.

What to do about the dwindling stock of antibiotics

October 13, 2014 8:57 am | by Diana Lutz, Washington Univ. in St. Louis | News | Comments

The Centers for Disease Control and Prevention has said that at least 2 million Americans are sickened by antibiotic resistant infections each year and survive. Twenty-three thousand die. These experiences leave deep impressions not just on the patients but on their family and friends.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading